Akebia joins GSK in oral CKD anaemia market March 28, 2024 AutoBot News 0 The FDA has approved Akebia Therapeutics’ vadadustat as a treatment for anaemia caused by chronic kidney disease (CKD) in dialysis patients, becoming the first rival to GSK’s Jesduvroq.